Clinical Trials Browser

Terminated × INDUSTRY × Paclitaxel × Clear all

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

Ovarian Neoplasms

NCT04832854 2026-03-11

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT04222972 2026-03-05

AcceleRET-Lung

Phase 3 Terminated

223 enrolled 18 charts

Head & NeckThoracic

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05381909 2026-02-20

A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor, Adult

NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Phase 2 Terminated

GynecologicSarcoma

Advanced Endometrial Cancer

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Phase 2 Terminated

36 enrolled 11 charts

Ovarian Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT02597036 2025-10-23

A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

Phase 1 Terminated

62 enrolled 25 charts

Other solid neoplasm

Solid Tumors

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT05326035 2025-10-02

A Study of WJ05129 in Advanced Malignant Solid Tumors

Phase 1/2 Terminated

Other solid neoplasm

Locally Advanced or Metastatic Malignant Solid Tumors

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06016270 2025-09-05

A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

Phase 1/2 Terminated

Extensive Stage Small Cell Lung Cancer

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06321068 2025-08-14

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Phase 2/3 Terminated

Endometrial Neoplasms

NCT03440437 2025-07-01

A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

Phase 1/2 Terminated

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT05311176 2025-05-11

nextHERIZON

Phase 2 Terminated

7 enrolled 8 charts

Gastrointestinal

Stomach Neoplasms

NCT06094296 2025-04-16

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

1 enrolled 4 charts

Lung Neoplasms

NCT05267470 2025-03-25

FORTITUDE-201

Phase 1 Terminated

74 enrolled 22 charts

Squamous-Cell Non-Small-Cell Lung Cancer

NCT05543629 2025-03-18

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

Phase 1/2 Terminated

36 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT04492033 2025-01-27

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Phase 1/2 Terminated

GastrointestinalOther solid neoplasm

P1b: Advanced Solid Tumors

NCT01705483 2024-11-07

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Phase 1 Terminated

Pharmacokinetics of ASP9853

NCT02470585 2024-10-26

VELIA

Phase 3 Terminated

1,140 enrolled 29 charts

Ovarian Neoplasms

NCT04325698 2024-10-01

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Phase 3 Terminated

8 enrolled 6 charts

Advanced Non-squamous NSCLC

NCT00807612 2024-09-25

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 1/2 Terminated

15 enrolled 11 charts

Insulin-Like Growth Factor I, Resistance To

NCT02134067 2024-09-05

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Phase 1 Terminated

Epilepsy, Neoplasms

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT01279291 2024-04-26

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Phase 1 Terminated

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT04761601 2024-03-13

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumor

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03840902 2024-01-16

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

153 enrolled 13 charts

Carcinoma, Non-Small-Cell Lung

NCT05193604 2023-12-08

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Phase 1 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT02826161 2023-11-15

CanStem43L

Phase 3 Terminated

4 enrolled 6 charts

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04729608 2023-10-30

AXLerate-OC

Phase 3 Terminated

Ovarian Neoplasms

NCT03892018 2023-05-22

The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Phase 1 Terminated

Other solid neoplasm

Solid Tumor, Adult

NCT03588039 2023-05-19

Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor

NCT02761694 2023-05-06

MK-4440-001

Phase 1 Terminated

78 enrolled 28 charts

Neoplasms

NCT00272987 2023-04-28

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase 3 Terminated

63 enrolled 22 charts

Breast Neoplasms

NCT02322814 2023-04-13

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Phase 2 Terminated

169 enrolled 31 charts

Breast Neoplasms

NCT03019588 2023-03-30

MK-3475-063

Phase 3 Terminated

94 enrolled 17 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03138889 2023-03-10

PROPEL

Phase 1/2 Terminated

162 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT03894540 2022-09-13

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Phase 1 Terminated

22 enrolled 27 charts

Other solid neoplasm

Solid Tumor

NCT03064854 2022-08-15

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung

NCT04210037 2022-07-12

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Terminated

Small Cell Lung Carcinoma

NCT00479765 2022-06-22

A Phase 1 / 2 Dose Escalation Study of Locally-Administered OncoGel™ in Subjects With Recurrent Glioma

Phase 1/2 Terminated

4 enrolled 5 charts

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Recurrence

NCT03707028 2022-04-11

A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

Phase 1/2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT04221828 2022-03-29

Trial of NanoPac Focal Therapy for Prostate Cancer

Phase 2 Terminated

1 enrolled 5 charts

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT03690739 2022-02-24

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Phase 3 Terminated

Ovarian Neoplasms

NCT04031885 2021-08-24

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Phase 4 Terminated

4 enrolled 9 charts

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

Phase 2 Terminated

66 enrolled 40 charts

Breast Neoplasms